$63MSeries B, 22 September 2025
Series B2 to advance lead candidate AHB-137 toward first-in-class data and a planned FDA filing.
- Amount
- $63M
- Stage
- Series B
- Announced
- 22 September 2025
- Lead
- Qiming Venture Partners
- Use of funds
- Series B2 to advance lead candidate AHB-137 toward first-in-class data and a planned FDA filing.
- Checked
- Announced by the company
- Sources
- AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepati biospace.com
AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepati news.google.com